Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
暂无分享,去创建一个
[1] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[2] João Costa,et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials , 2006, BMJ : British Medical Journal.
[3] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[4] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[5] S. Yusuf,et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.
[6] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.
[7] Peter Jüni,et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. , 2006, American heart journal.
[8] Simon Davies,et al. Epidemiology: Study Design and Data Analysis , 2006 .
[9] Charles E. McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[10] N J Wald,et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials , 2003, BMJ : British Medical Journal.
[11] Robert M Califf,et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.
[12] W. Kirch,et al. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction , 2001, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[13] Neil Chapman,et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. , 2005, Archives of internal medicine.
[14] Jonathan C Craig,et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. , 2006, Journal of the American Society of Nephrology : JASN.
[15] G. Bouvenot,et al. Antiplatelet therapy for primary prevention in diabetes. , 2006, Diabetes & metabolism.
[16] M. Woodward,et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. , 2003, Diabetes care.
[17] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[18] F. Turnbull. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.
[19] P. Steg,et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. , 2006, Archives of internal medicine.
[20] Kenneth F Schulz,et al. Multiplicity in randomised trials I: endpoints and treatments , 2005, The Lancet.
[21] G. Mancia,et al. Systolic and diastolic blood pressure control in antihypertensive drug trials. , 2002, Journal of hypertension.
[22] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[23] R. Collins,et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.
[24] G. Duvel. The study group. , 1980 .
[25] M. Woodward,et al. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia–Pacific region , 2007, Journal of hypertension.
[26] R. Cooper,et al. Hypertension Treatment and Control in Five European Countries, Canada, and the United States , 2004, Hypertension.
[27] W. Kannel,et al. Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.
[28] P. Priest,et al. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated , 2000, BMJ : British Medical Journal.
[29] Jing Chen,et al. Prevalence, Awareness, Treatment, and Control of Hypertension in China , 2002, Hypertension.
[30] A. Hughes,et al. Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. , 2007, Contemporary clinical trials.
[31] C. Lau,et al. Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999–2004 , 2007, Hypertension.